We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

WONDFO

Wondfo is a high-tech biological company focusing providing professional products and services for rapid diagnosis an... read more Featured Products: More products

Download Mobile App





Wondfo Exhibits Automatic Bench-Top CLIA Analyzers for POC Testing at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Wondfo (Guangzhou, China) will be exhibiting its automatic bench-top chemiluminescence immunoassay (CLIA) analyzers with advanced features for point of care (POC) testing at the 2022 AACC Clinical Lab Expo. More...



At AAC 2022, Wondfo is presenting its compact and automatic Accre 8 and Accre 90 CLIA bench-top analyzers which are 70% smaller than ordinary CLIA analyzers. With a single-dose reagent cartridge, the analyzers allow 600 days MTBF, requiring no extra consumables. The Accre 8 and Accre 90 enjoy both simple operation requiring only 30-minute training and reliable calibration & quality control system. Both the analyzers have a TAT time of 12-40 minutes and offer high sensitivity.

The Accre 8 has a throughput of up to 36 tests/hour and offers carry-over prevention. The Accre 90 has a throughput of up to 96 tests/hour and enables simultaneous processing of difference parameters with carry-over prevention. The Accre 8 and Accre 90 are designed for multiple application scenarios in emergency care, primary care and laboratories. Both the analyzers offer a broad menu of tests in the areas of thyroid, fertility, tumors, infectious diseases, cardiac, anemia, inflammation, bone metabolism and glycol metabolism.
 

Related Links:
Wondfo 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.